HER2 Proven Diagnostic Accuracy
HER2 treatment targets both patients with breast and gastric cancer indications.
Since 1998, laboratories around the world have relied on the diagnostic accuracy of Dako HER2 testing for breast cancer. Herceptin® therapy has now become a standard of care for HER2-overexpressing metastatic breast cancer, and a pharmDx™ test for HER2 protein overexpression or HER2 gene amplification is conducted to assess Herceptin® eligibility.
In addition a recent clinical study shows that HercepTest™ and HER2 FISH pharmDx™ Kit accurately identify patients with gastric cancer who may benefit from trastuzumab treatment (Lancet 2010; 376:687-07).
Dako has also received approval from the U.S. FDA to expand the use of the HercepTest™ and HER2 pharmDx™ Kits to include patients with metastatic gastric or gastricesophageal junction adenocarcinoma (Lancet 2010; 376:687-07).
Leading pathologists endorse and use HercepTest™: See and hear why!
Would you like further information? Please contact your local Dako representative for additional material.